June 27, 2017 09:41 AM EDTUpdated 10:23 AM
News Briefing

Mi­to­conix lands $20M to de­vel­op neu­rode­gen­er­a­tive plat­form out of Stan­ford; RaNA gets a new name fol­low­ing mR­NA deal with Shire

Shehla Shakoor

Managing Director

→ Mi­to­conix has a neu­rode­gen­er­a­tion plat­form tech from Stan­ford and a base in Is­rael from which it plans to push its lead ther­a­py in­to clin­i­cal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times